Electromed Launches SmartVest Connect Mobile Application

Electromed Inc. has launched its SmartVest Connect App for iOS and Android, a personalized high frequency chest wall oscillation (HFCWO) therapy management portal for patients with compromised pulmonary function. The SmartVest Connect app securely connects to the SmartVest SQL through Bluetooth technology. This interface allows patients and healthcare teams to track therapy in real-time and collaborate on care decisions to improve therapy adherence and patient outcomes.
 
Available for download on the App Store and Google Play, the SmartVest Connect app allows patients to more seamlessly connect with their SmartVest therapy and offers new capabilities designed for mobile, including setting personal therapy reminders and real-time therapy monitoring.
 
“Since launch in 2017, SmartVest Connect has enhanced treatment plans for patients with bronchiectasis and other chronic lung conditions that require ongoing airway clearance therapy,” said Kathleen Skarvan, president and CEO of Electromed. “Beginning today, patients can enjoy the benefits of staying connected to their HFCWO therapy right from their mobile device.”
 
Patients currently using SmartVest Connect can access their account through the SmartVest Connect app. Once downloaded from the App Store or Google Play, patients will receive their therapy performance metrics automatically. During each new therapy session, patients can view real-time data from their mobile device and set helpful therapy reminders that fit their lifestyle.
 
Skarvan said: “As our mission is to help patients breathe easier and live better by providing effective, market-driven HFCWO solutions, this new feature will enhance our customers’ experiences and allow them to take a more active role in their therapy, monitoring performance wherever life takes them next.”
 
Electromed is using Home Medical Equipment distributors (one national and one regional) to distribute and sell the SmartVest Airway Clearance System in the United States home care market.
 
Bronchiectasis is under recognized and underdiagnosed, representing the fastest growing diagnostic category and we believe it holds the greatest potential for high frequency chest wall oscillation (HFCWO) growth in the United States. Bronchiectasis is an irreversible, chronic lung condition characterized by enlarged and permanently damaged bronchi. The condition is associated with recurrent lower respiratory infections, inflammation, reduction in pulmonary function, impaired respiratory secretion clearance, increased hospitalizations and medication use, and increased morbidity and mortality.
 
The SmartVest uses HFCWO, a proven therapy that helps clear the lungs of excess secretions, reducing the risk of respiratory infections and hospitalizations. The SmartVest system is designed to make HFCWO treatments as effective, convenient, and comfortable as possible, so patients can breathe easier and live better with improved respiratory function. Electromed is the only HFCWO therapy company with multiple published clinical studies showing a significant reduction in exacerbation rates and improvement in quality of life in bronchiectasis patients using its SmartVest system.^1-3
 
References
¹ Sievert CE et al. Respiratory Therapy Journal. 2016;11(4): 34–38.
² Sievert CE et al. Respiratory Therapy Journal. 2018;13(2): 38–41.
³ Powner J et al. BMC Pulmonary Medicine. 2019;19(82).